Structure Therapeutics (GPCR) investor relations material

Executive summary

• Aleniglipron entered Phase 3 in August 2026; ACCOMPLISH-1 and -2 topline data are expected in H2 2028.

• Q3 net loss was $144.8M amid increased R&D investment; $1.24B in cash and investments is expected to fund operations and key milestones through end-2028.

Financial highlights

• Q3 operating expenses were $156.3M versus $73.8M year over year, including R&D of $134.6M and G&A of $21.8M.

• Q3 net loss was $144.8M versus $65.7M; interest and other income was $11.7M versus $8.2M.

• Q3 R&D expense was $134.6M versus $59.0M, and G&A was $21.8M versus $14.8M; R&D reflected clinical trial, preclinical and employee costs.

• Nine-month operating expenses were $364.3M versus $200.5M; net loss was $326.9M versus $174.2M.

• Nine-month R&D was $301.1M versus $156.6M; G&A was $63.2M versus $44.0M.

Outlook and guidance

• $1.24B in cash, cash equivalents and short-term investments is expected to fund projected operations and key clinical milestones through end-2028; estimate excludes pre-commercialization costs, including commercial manufacturing.

• Aleniglipron body-composition, T2DM and SWITCH study data are expected in Q4 2026; ACCG-2671 MAD results are expected in H1 2027.

• ACCOMPLISH-1 and -2 topline results are expected in H2 2028; a Phase 1 trial of ACCG-3535 was planned for Q4 2026, with an oral amylin/GLP-1 combination trial planned for 2027.

• R&D and operating losses are expected to increase as clinical trials, pipeline work, hiring and commercialization preparation advance.